List of Excipients in Branded Drug SUFENTANIL CITRATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Akorn	SUFENTANIL CITRATE	sufentanil citrate	17478-050	WATER

Generic Drugs Containing SUFENTANIL CITRATE

Company	Ingredient	NDC	Excipient
Hospira Inc	sufentanil citrate	0409-3382	HYDROCHLORIC ACID
Hospira Inc	sufentanil citrate	0409-3382	SODIUM HYDROXIDE
Hospira Inc	sufentanil citrate	0409-3382	WATER
Hikma Pharmaceuticals USA Inc	sufentanil citrate	0641-6110	CITRIC ACID MONOHYDRATE
Hikma Pharmaceuticals USA Inc	sufentanil citrate	0641-6110	WATER

What are the Most Frequently-Used Excipients in SUFENTANIL CITRATE?

# Of NDCs	Excipient
1	CITRIC ACID MONOHYDRATE
1	HYDROCHLORIC ACID
1	SODIUM HYDROXIDE
2	WATER

Sufentanil Citrate Excipient Strategy and Commercial Opportunities

Last updated: August 28, 2026

Sufentanil citrate is a high-potency synthetic opioid used mainly in injectable anesthesia and acute-pain products. Its excipient strategy differs by dosage form: injectable products prioritize sterility, isotonicity, pH control, and container compatibility, while sublingual tablets prioritize rapid disintegration, dose uniformity, mucosal absorption, taste control, and opioid-resistant handling. The strongest commercial opportunities are in hospital-use products, differentiated sublingual delivery, ready-to-administer presentations, and manufacturing platforms that improve stability and abuse-deterrence without delaying onset.

What is the FDA-approved role of sufentanil citrate?

Sufentanil citrate is the salt form of sufentanil. It is approximately five to ten times more potent than fentanyl and is used in controlled medical settings for anesthesia and severe acute pain.

The principal dosage forms are:

Product type	Typical strength	Primary setting	Excipient priorities
Injection	50 mcg/mL sufentanil base equivalent	Operating room, intensive care, anesthesia	Sterility, isotonicity, pH, adsorption control
Sublingual tablet	30 mcg sufentanil base equivalent	Medically supervised acute-pain treatment	Rapid disintegration, taste, dose uniformity, mucosal delivery
Investigational transmucosal systems	Variable	Acute pain and procedural use	Mucoadhesion, controlled release, abuse deterrence

FDA approved DSUVIA, a 30-mcg sublingual sufentanil tablet, in 2018 for adults with acute pain severe enough to require an opioid analgesic when alternative treatments are inadequate. The product is restricted to certified medically supervised settings and is not approved for outpatient home use.[1]

Sufentanil injection products have long been used in anesthesia. Generic injectable products compete primarily on price, supply reliability, preservative strategy, container configuration, and institutional contracting.

What excipients are used in sufentanil citrate products?

Public labeling identifies materially different excipient systems for injection and sublingual delivery.

Sufentanil citrate injection excipients

Sufentanil citrate injection commonly contains sodium chloride and water for injection. Hydrochloric acid or sodium hydroxide may be used for pH adjustment, depending on the manufacturer and presentation.[2]

The formulation is relatively simple because the active pharmaceutical ingredient is delivered directly into the bloodstream. The key technical risks are not tablet performance but:

• Sterility assurance
• Endotoxin control
• Particulate matter
• pH stability
• Container-closure integrity
• Adsorption to glass, elastomer, or polymer components
• Compatibility with infusion systems
• Concentration uniformity in small-volume containers

The commercial value of a new injectable excipient system is therefore limited unless it solves a specific manufacturing or clinical problem. Examples include reduced adsorption, lower extractables and leachables, extended in-use stability, or compatibility with prefilled syringes and ready-to-administer bags.

DSUVIA sublingual tablet excipients

The DSUVIA label identifies mannitol, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate as inactive ingredients.[1]

Their functional roles are conventional but important:

Excipient	Likely formulation function
Mannitol	Diluent, mouthfeel modifier, water-soluble matrix component
Microcrystalline cellulose	Compression aid, structural diluent
Croscarmellose sodium	Superdisintegrant
Magnesium stearate	Lubricant

At a 30-mcg dose, the active represents a very small fraction of total tablet mass. Content uniformity, segregation control, blend homogeneity, and low-dose assay are central development issues. The excipient system must produce a tablet that is mechanically robust during packaging and transport but disintegrates quickly under the tongue.

The label does not disclose the complete quantitative formula or the manufacturing process. Public excipient identification therefore supports a functional assessment but does not establish the exact commercial formulation design.[1]

What excipient properties matter most for sublingual sufentanil?

The optimal sublingual formulation must balance five competing requirements: rapid tablet breakup, reliable drug release, acceptable taste, physical strength, and consistent absorption.

Rapid disintegration

Croscarmellose sodium is suitable for rapid water uptake and tablet breakup. Excessive compression force or excessive lubricant can slow disintegration. The formulation developer must control:

• Tablet hardness
• Porosity
• Particle-size distribution
• Compression dwell time
• Lubrication time
• Residual moisture

A faster-disintegrating tablet can improve early exposure, but faster breakup does not automatically establish faster clinical onset. Dissolution, saliva volume, mucosal permeability, swallowing fraction, and patient technique also influence pharmacokinetics.

Low-dose content uniformity

Sufentanil is potent at microgram quantities. A formulation can meet average assay requirements while failing unit-to-unit uniformity if the active segregates during blending or filling.

Preferred strategies include:

• Geometric dilution
• Ordered mixing
• Carrier-based premixes
• Controlled particle-size distribution
• Granulation where justified
• In-process blend sampling
• Weight-based and assay-based release controls
• Low-shear transfer systems

Excipient selection must be evaluated together with the API particle morphology and electrostatic behavior. Mannitol and microcrystalline cellulose can provide a workable bulk matrix, but the appropriate grade and particle-size relationship are critical.

Taste and mouthfeel

Sufentanil citrate can create a bitter or unpleasant oral sensation. Mannitol can improve mouthfeel and provide a cooling sensation, but it may not fully mask opioid bitterness. Potential approaches include:

• Ion-exchange resins
• Polymer coatings
• Cyclodextrin complexes
• Lipid-based taste barriers
• Flavor systems compatible with sublingual use
• Coated API particles
• Rapidly dissolving protective matrices

Taste masking must not materially delay transmucosal release. A coating that prevents bitterness but increases swallowing can reduce sublingual exposure and convert the product into a slower gastrointestinal delivery system.

Mucoadhesion

A modest level of mucoadhesion may improve retention under the tongue. Candidates include selected grades of polyacrylic acid, hydroxypropyl cellulose, hydroxypropyl methylcellulose, and other mucosal polymers.

The commercial target is controlled retention, not maximal adhesion. Excessive adhesion can create poor patient acceptability, variable residence time, and difficult tablet removal in emergency settings.

Stability and moisture control

Sublingual tablets are vulnerable to moisture uptake, which can alter hardness, disintegration, assay, and impurity formation. Commercial packaging may require:

• High-barrier blister materials
• Unit-dose foil packaging
• Desiccant-controlled secondary packaging
• Low-humidity manufacturing
• Moisture-sensitive process controls
• Stability testing after package opening

A formulation with slightly slower disintegration but materially better stability can have stronger commercial value than a fast tablet that requires expensive packaging or narrow storage controls.

What formulation patents protect sublingual sufentanil?

The principal protectable features are usually the dosage form, delivery system, manufacturing process, and method of use rather than the basic excipients themselves.

Potential claim categories include:

1. A sublingual tablet containing sufentanil or a pharmaceutically acceptable salt.
2. A specified disintegration or dissolution profile.
3. A defined ratio of mannitol, cellulose, disintegrant, and lubricant.
4. A tablet with a specified dose-uniformity range.
5. A transmucosal delivery system with defined pharmacokinetic parameters.
6. A package configuration that controls moisture or dose access.
7. A method of treating acute pain in a medically supervised setting.
8. A manufacturing process for distributing microgram quantities of sufentanil uniformly.

Conventional mannitol, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate are generally weak standalone patent subjects. Patent strength increases when the excipients are linked to a non-obvious performance result, such as unusually rapid onset, improved content uniformity, reduced swallowing, or a defined stability profile.

For a commercial diligence review, the relevant sources are the FDA Orange Book, issued patents and patent-family records, assignment data, prosecution history, and litigation records. A formulation competitor should not assume that substitution of one conventional excipient avoids infringement. Claims may be written around functional results, dosage-form architecture, manufacturing steps, or ranges rather than exact excipient identity.

What is the Orange Book and regulatory status of DSUVIA?

DSUVIA is an FDA-approved prescription product with significant use restrictions. FDA required a Risk Evaluation and Mitigation Strategy because of the risks associated with accidental exposure, respiratory depression, medication errors, and abuse.[3]

The regulatory restrictions affect commercial design:

• Use is limited to certified medically supervised settings.
• The product is not intended for home dispensing.
• The product is not positioned as a routine chronic-pain medicine.
• Packaging must support controlled administration and inventory management.
• Training and institutional controls influence adoption.
• Distribution economics depend on hospitals, military medicine, emergency departments, and procedural settings.

The formulation strategy must therefore support health-system workflows. A unit-dose tablet in a tamper-evident package may have more value than a multidose bottle, even if the underlying tablet composition is similar.

When does sufentanil citrate lose exclusivity?

Sufentanil citrate as an active ingredient is an old small molecule, and basic compound protection is no longer the principal barrier to generic competition. The commercial barriers are more likely to involve:

• Product-specific formulation patents
• Delivery-system patents
• Method-of-use patents
• Manufacturing patents
• FDA exclusivity tied to a particular approval
• Controlled-substance registration and supply controls
• Specialized packaging and institutional distribution
• Clinical adoption and purchasing contracts

Generic injectable sufentanil products already compete in the market. A sublingual sufentanil competitor may face a different pathway because it must match the reference product’s dosage form, strength, route, labeling, and bioequivalence requirements.

Patent expiration dates must be assessed by product and patent family. The expiration of a basic sufentanil patent does not necessarily eliminate barriers created by later sublingual delivery or formulation patents. Conversely, an unexpired formulation patent may have limited commercial value if a competitor can develop a non-infringing tablet with comparable clinical performance.

What generic entry risks exist for sublingual sufentanil?

The principal generic risk is a 30-mcg sublingual tablet that uses different excipients but delivers comparable clinical performance.

High-risk generic pathways

A challenger could pursue:

• An abbreviated new drug application with a Q1/Q2-equivalent formulation
• A formulation using alternative diluents or disintegrants
• A different taste-masking technology
• A direct-compression tablet with comparable disintegration
• A rapidly disintegrating tablet using a proprietary polymer matrix
• A unit-dose product designed for hospital administration

The risk is highest if the reference product has limited formulation complexity and its key patent claims require exact excipient identities or narrow quantitative ranges.

Barriers that can slow entry

Entry is more difficult when the reference product has:

• A narrow therapeutic index or difficult bioequivalence profile
• A protected transmucosal pharmacokinetic profile
• Complex content-uniformity controls
• Specialized packaging
• A restricted distribution model
• Limited availability of clinical or commercial reference samples
• Patents covering manufacturing or dose-delivery performance

Because sufentanil is highly potent, regulators and sponsors will scrutinize dose uniformity, accidental exposure, container integrity, and manufacturing controls. These controls raise development and inspection risk even when the formulation is chemically simple.

Which excipient strategies offer the strongest commercial opportunities?

Hospital-ready sublingual tablets

A competitor can differentiate through improved handling rather than a radically different excipient list. Opportunity areas include:

• Faster disintegration
• Better taste
• Lower moisture sensitivity
• Improved tablet strength
• Easier administration under anesthesia or emergency conditions
• Barcode-enabled unit-dose packaging
• Reduced medication-error risk

The strongest product would combine rapid transmucosal delivery with reliable storage and clear administration instructions.

Ready-to-administer injections

For injectable sufentanil, opportunities include:

• Prefilled syringes
• Ready-to-use diluted concentrations
• Polymer-compatible presentations
• Reduced adsorption systems
• Longer in-use stability
• Low-waste packaging
• Standardized concentrations for anesthesia workflows

The value proposition is operational. Hospitals may adopt a product that reduces compounding, preparation time, syringe labeling, and dosing errors.

Abuse-deterrent systems

An abuse-deterrent sublingual formulation could use physical barriers, aversive excipients, or extraction-resistant matrices. The difficulty is preserving rapid onset. A strong platform would reduce manipulation or extraction while maintaining sublingual performance.

The regulatory and market value depends on the abuse-deterrence claim, labeling, clinical evidence, and payer or institutional demand. A merely unpleasant-tasting product is unlikely to justify substantial pricing without demonstrated misuse-resistance.

Combination products and procedural analgesia

Sufentanil could be paired with procedural delivery systems, such as controlled-dose applicators or clinician-administered transmucosal devices. These products may compete on administration precision and workflow rather than active-ingredient novelty.

The main risks are device classification, dose-control validation, human-factors testing, and controlled-substance security.

How does sufentanil compare with fentanyl excipient opportunities?

Factor	Sufentanil	Fentanyl
Potency	Very high	High
Dose-uniformity challenge	Severe	Severe
Established dosage forms	Injectable, sublingual	Injectable, transdermal, buccal, nasal, oral
Excipient differentiation	More limited but potentially defensible in sublingual systems	Broader, with more established delivery platforms
Generic competition	Strong in injection; narrower in specialized sublingual forms	Strong across several dosage forms
Abuse-deterrence opportunity	High because of potency and controlled administration	High but crowded
Hospital workflow opportunity	Ready-to-administer injection and sublingual acute pain	Broad across anesthesia, emergency, chronic, and breakthrough pain

Fentanyl has a larger commercial and patent history in transmucosal systems. Sufentanil offers a smaller market but may support premium positioning where microgram dosing, rapid onset, and supervised administration solve a specific hospital problem.

How strong is the patent estate for excipient-based sufentanil products?

Patent strength is highest when a claim combines:

• A defined sufentanil dose
• A specific sublingual architecture
• A measurable disintegration or dissolution result
• A pharmacokinetic benefit
• A manufacturing control for microgram uniformity
• A package or device that limits exposure or misuse

Patent strength is lower for claims directed only to the use of common excipients without a demonstrated technical effect.

A commercial entrant should prioritize freedom-to-operate analysis around product-by-process claims, functional dissolution limits, dose-delivery devices, and method-of-use claims. Substituting croscarmellose sodium with another superdisintegrant may avoid a composition claim but still implicate a performance-based claim.

What licensing and partnering opportunities exist?

Licensing value is concentrated in delivery technology, not in sufentanil citrate itself.

Potential partners include:

• Specialty pharmaceutical companies with controlled-substance infrastructure
• Hospital injectables manufacturers
• Drug-delivery companies with sublingual platforms
• Contract manufacturers experienced in microgram-dose products
• Packaging companies with high-barrier unit-dose systems
• Military and emergency-care suppliers
• Institutional distributors with restricted-product capabilities

A licensing transaction would likely require rights to a delivery platform, formulation patent family, manufacturing process, or regulatory dossier. A simple excipient substitution is less likely to command meaningful licensing economics unless it creates a clear regulatory, stability, or cost advantage.

What revenue exposure and competitive risks should investors monitor?

Revenue potential depends on institutional adoption, supply reliability, and pricing relative to injectable opioids and alternative acute-pain products. The sublingual market is constrained by supervised-use requirements, while injectable products face established generic pricing pressure.

Key commercial indicators include:

• Number of certified institutions
• Hospital formulary placement
• Annual unit volume
• Average selling price
• Controlled-substance quota availability
• Manufacturing yield
• Product discontinuation or shortage notices
• Contract wins with government or military buyers
• Patent litigation or Paragraph IV activity
• FDA label changes affecting setting or administration

The primary downside risk is a formulation that offers clinical differentiation without enough workflow or economic benefit to justify premium pricing.

Key Takeaways

• Sufentanil citrate has two distinct excipient strategies: simple sterile aqueous injection and performance-sensitive sublingual tablets.
• DSUVIA uses mannitol, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate according to its FDA label.[1]
• The main sublingual development risks are microgram-dose uniformity, rapid disintegration, taste, moisture stability, and controlled administration.
• Conventional excipients have limited standalone patent value. Defensible protection usually requires a measurable delivery, stability, manufacturing, or abuse-deterrence advantage.
• Injectable commercial opportunities center on prefilled syringes, ready-to-administer products, adsorption control, and workflow reduction.
• Sufentanil is a small molecule, so biosimilar risk is not applicable. Generic and formulation-copying risk are the relevant threats.
• The most attractive partnerships involve delivery platforms, manufacturing controls, packaging, and institutional distribution.
• Product-specific Orange Book and patent-family review is essential because basic active-ingredient exclusivity does not determine the remaining barrier to sublingual generic entry.

FAQs

Is mannitol necessary in a sufentanil sublingual tablet?

No. Mannitol is a useful diluent and mouthfeel modifier, but alternative fillers or co-processed excipients may be used if the product maintains dose uniformity, stability, disintegration, and bioequivalence.

Can a sufentanil sublingual tablet use a different superdisintegrant?

Yes. A challenger may use another superdisintegrant, but the substitution must preserve tablet performance and avoid claims covering the selected ingredient, quantitative range, process, or functional dissolution profile.

Are preservatives appropriate for sufentanil citrate injection?

Preservative selection depends on the container, dose presentation, route, labeling, and regulatory strategy. Single-dose parenteral products commonly emphasize preservative-free formulations, while multidose products require a separate microbiological and regulatory assessment.

What packaging best protects sublingual sufentanil tablets?

Unit-dose, high-barrier blister packaging is generally the strongest commercial option because it limits moisture exposure, supports controlled administration, and reduces handling of a highly potent opioid.

Can excipient changes trigger a new FDA application for sufentanil?

They can. The regulatory impact depends on the dosage form, extent of formulation change, product sameness, manufacturing process, bioequivalence requirements, and whether the change affects labeling or clinical performance.

References

1. U.S. Food and Drug Administration. (2018). DSUVIA (sufentanil citrate) sublingual tablet prescribing information. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (n.d.). Sufentanil citrate injection prescribing information. https://dailymed.nlm.nih.gov
3. U.S. Food and Drug Administration. (2018). FDA approves new opioid for use in medically supervised settings. https://www.fda.gov
4. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
5. U.S. Food and Drug Administration. (n.d.). Risk Evaluation and Mitigation Strategies. https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems